Anti-tumor activity of metformin: from metabolic and epigenetic perspectives

Xilan Yu; Wuxiang Mao; Yansheng Zhai; Chong Tong; Min Liu; Lixin Ma; Xiaolan Yu; Shanshan Li

doi:10.18632/oncotarget.13639

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Anti-tumor activity of metformin: from metabolic and epigenetic perspectives

Xilan Yu, Wuxiang Mao, Yansheng Zhai, Chong Tong, Min Liu, Lixin Ma, Xiaolan Yu and Shanshan Li _

PDF | HTML | How to cite

Oncotarget. 2017; 8:5619-5628. https://doi.org/10.18632/oncotarget.13639

Metrics: PDF 3605 views | HTML 5326 views | ?

Abstract

Xilan Yu1,*, Wuxiang Mao1,*, Yansheng Zhai1, Chong Tong1, Min Liu1, Lixin Ma1, Xiaolan Yu1, Shanshan Li1

1Hubei Collaborative Innovation Center for Green Transformation of Bio-Resources, College of Life Sciences, Hubei University, Wuhan, Hubei, China

*These authors have equally contributed to this work

Correspondence to:

Xiaolan Yu, email: [email protected]

Shanshan Li, email: [email protected]

Keywords: metformin, therapeutic targets, metabolism, epigenetic modifications

Received: September 22, 2016 Accepted: November 03, 2016 Published: November 26, 2016

ABSTRACT

Metformin has been used to treat type 2 diabetes for over 50 years. Epidemiological, preclinical and clinical studies suggest that metformin treatment reduces cancer incidence in diabetes patients. Due to its potential as an anti-cancer agent and its low cost, metformin has gained intense research interest. Its traditional anti-cancer mechanisms involve both indirect and direct insulin-dependent pathways. Here, we discussed the anti-tumor mechanism of metformin from the aspects of cell metabolism and epigenetic modifications. The effects of metformin on anti-cancer immunity and apoptosis were also described. Understanding these mechanisms will shed lights on application of metformin in clinical trials and development of anti-cancer therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13639

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Anti-tumor activity of metformin: from metabolic and epigenetic perspectives

Abstract